tyrosine has been researched along with Parkinson Disease in 213 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (36.62) | 18.7374 |
| 1990's | 31 (14.55) | 18.2507 |
| 2000's | 49 (23.00) | 29.6817 |
| 2010's | 42 (19.72) | 24.3611 |
| 2020's | 13 (6.10) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida, TO; Portugal, CC; Relvas, JB; Socodato, R | 1 |
| Amstrup, SK; Bjerrum, MJ; Christiansen, G; Costeira-Paulo, J; Davies, MJ; Grønnemose, AL; Ilag, LL; Jørgensen, TJD; Landreh, M; Marklund, EG; Møller, IM; Nielsen, J; Österlund, N; Otzen, DE; Pedersen, JN; Pedersen, JS; Rao, RSP; Sahin, C; Tiwari, MK; Østerlund, EC | 1 |
| Ayaki, T; Chiba, S; Hirai, H; Hirotsune, S; Ishida, R; Jin, M; Komai, S; Konno, A; Matsumoto, S; Nakajima, H; Taguchi, T; Takahashi, R; Takao, T; Togawa, N; Yamakado, H | 1 |
| Jiang, M; Jin, W; Lai, X; Ma, H; Shen, M; Sun, D; Wu, J; Yan, J; Yin, S; Zhang, Y | 1 |
| Ai, P; He, X; Lai, Y; Mo, C; Qian, Y; Song, Y; Xiao, Q; Xu, S; Yan, Z; Yang, X; Zhang, Y | 1 |
| Cheng, J; Lin, WY; Liu, HP; Wu, BT | 1 |
| Bandookwala, M; Sengupta, P | 1 |
| Churchill, MJ; Liguore, WA; Massaquoi, MS; Melrose, HL; Meshul, CK; Moore, C | 1 |
| Buratti, FA; Carloni, P; Fernandez, CO; Palomino-Hernandez, O; Rossetti, G; Sacco, PS | 1 |
| Hu, W; Krischek, B; Wang, C; Zheng, F; Zhou, J | 1 |
| Belsom, A; Bieschke, J; Binolfi, A; Rappsilber, J; Selenko, P; Shah, M; Theillet, FX; Verzini, S; Wanker, EE | 1 |
| Babu, GN; Gupta, M; Paliwal, VK | 1 |
| Bahri, MA; Becker, G; Bezard, E; Caruso, M; Citron, M; De Wolf, C; Deprez, T; Downey, P; Frequin, JM; Freyssin, A; Garraux, G; Gillent, E; Hustadt, F; Jacquin, L; Lemaire, C; Luxen, A; Mairet-Coello, G; Michel, A; Plenevaux, A | 1 |
| Arshad, M; Wang, W; Xu, L; Yu, M; Zhao, D; Zhou, L | 1 |
| Chiki, A; De Genst, E; Di Trani, J; Dobson, CM; El Turk, F; Fauvet, B; Guilliams, T; Hejjaoui, M; Lashuel, HA; Mittermaier, A; Vendruscolo, M | 1 |
| Cordaro, M; Crupi, R; Cuzzocrea, S; D'Amico, R; Di Paola, R; Gugliandolo, E; Impellizzeri, D; Peritore, AF; Siracusa, R | 1 |
| Feng, JH; Hu, XL; Lin, J; Lv, XY; Wang, BL; Wang, H; Xiong, F; Ye, WC; Zhang, XQ | 1 |
| Baraldi, E; D'Andrea, G; Giordano, G; Gucciardi, A; Leon, A; Pizzolato, G; Stocchero, M | 1 |
| Chacón, J; Fernández, E; García-Moreno, JM; Martín de Pablos, A | 2 |
| Soloway, AH; Soloway, PD; Warner, VD | 1 |
| Cannon, JR; Greenamyre, JT; Tapias, V | 1 |
| Dyrnesli, H; Ferapontova, EE; Lopes, P; Lorenzen, N; Otzen, D | 1 |
| Bendlin, BB; Buyan-Dent, L; Christian, BT; DeJesus, OT; Gallagher, CL; Harding, SJ; Holden, JE; Li, CT; Nickles, RJ; Oh, J; Okonkwo, O; Palotti, M; Stone, CK | 1 |
| Cai, Z; Chen, LL; Chua, KK; Li, M; Liu, LF; Luan, H; Meng, N; Mok, VC; Song, JX; Tang, Z; Xie, LX | 1 |
| Jin, G; Kang, H; Sun, S; Zhao, Y | 1 |
| Brzozowski, MJ; Jenner, P; Rose, S | 1 |
| Anantharam, V; Gordon, R; Harischandra, DS; Jin, H; Kanthasamy, A; Kanthasamy, AG; Kanthasamy, K; Lawana, V; Luo, J; Neal, M; Panicker, N; Saminathan, H; Sarkar, S | 1 |
| Chen, M; Du, T; Duan, C; Gao, G; Liu, J; Wang, Y; Yang, H | 1 |
| Hirayama, M; Ohno, K; Tsuda, T; Tsunoda, M; Yamamoto, M | 1 |
| Braus, GH; Kleinknecht, A; Lázaro, DF; Outeiro, TF; Pinho, R; Popova, B; Valerius, O | 1 |
| Abdul-Sada, A; Al-Hilaly, YK; Biasetti, L; Blakeman, BJ; Pollack, SJ; Serpell, LC; Thorpe, JR; Xue, WF; Zibaee, S | 1 |
| Herrman, L; Kinkel, M; Muhlack, S; Müller, T | 1 |
| Bahri, MA; Becker, G; Garraux, G; Hustadt, F; Lemaire, C; Luxen, A; Michel, A; Plenevaux, A | 1 |
| Barry, CH; Fink, AL; Ulrih, NP | 1 |
| Lutz, EA; Pielak, GJ; Ruf, RA; Zigoneanu, IG | 1 |
| Kuhn, W; Müller, T | 1 |
| Fukuda, T; Fukumitsu, N; Kiyono, Y; Suzuki, M | 1 |
| Muhlack, S; Müller, T | 2 |
| Andersen, JK; Danielson, SR; Gibson, BW; Held, JM; Oo, M; Schilling, B | 1 |
| Chen, L; Feany, MB; Hyman, BT; McLean, PJ; Negro, A; Periquet, M; Wang, X | 1 |
| Min, K; Park, DH; Yoo, YJ | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Alerte, TN; Daubner, SC; Di Monte, DA; Friedrich, EE; Hong, CS; Lou, H; Mader, SA; Marcus, BS; McCormack, AL; Montoya, SE; Pedersen, CJ; Peng, X; Perez, RG; Wang, J; Wu, J | 1 |
| Andreoni, S; Begni, B; Brighina, L; Difrancesco, JC; Ferrarese, C; Galbussera, A; Piazza, F; Piolti, R; Prigione, A | 1 |
| Bharath, MM; Dubey, SK; Harish, G; Misra, K; Mythri, RB | 1 |
| Houlden, H; Paisán-Ruiz, C | 1 |
| Caniglia, S; Impagnatiello, F; L'Episcopo, F; Marchetti, B; Morale, MC; Serra, PA; Testa, N; Tirolo, C | 1 |
| Asari, S; Fujimoto, K; Miyauchi, A; Muramatsu, S; Nakano, I; Sato, T | 1 |
| Dunn, JM; Rhoades, E; Sevcsik, E; Trexler, AJ | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Bendlin, BB; Buyan-Dent, L; Christian, BT; Dejesus, OT; Gallagher, CL; Harding, SJ; Holden, JE; Johnson, SC; Mueller, B; Nickles, RJ; Stone, CK | 1 |
| Daian, D; Dodiya, HB; Jaglin, JA; Keshavarzian, A; Kordower, JH; Mutlu, E; Shannon, KM | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Askmark, H; Johansson, A; Lennernäs, H; Nyholm, D | 1 |
| Dodiya, HB; Estes, JD; Forsyth, CB; Jaglin, JA; Keshavarzian, A; Kordower, JH; Shaikh, M; Shannon, KM; Voigt, RM | 1 |
| Cho, AR; Cho, JW; Ki, CS; Kim, HT; Kim, JS; Lee, WY; Shin, H | 1 |
| Choi, HS; Jang, A; Kim, YM; Lashuel, H; Liew, H; Suh, YH | 1 |
| Fauvet, B; Girault, HH; Lashuel, HA; Lu, Y; Prudent, M | 1 |
| Hirosawa, T; Kihira, K; Kimura, Y; Onzawa, Y; Shirasuna, M; Taogoshi, T; Uzuhashi, K | 1 |
| Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA | 1 |
| Cai, G; Friedman, E; Torres, C; Zhen, X | 1 |
| Biere, AL; Carpenter, JF; Chi, EY; Citron, M; Garzon-Rodriguez, W; Kendrick, BS; Krishnan, S; Li, C; Narhi, LO; Randolph, TW; Wood, SJ; Wypych, J | 1 |
| Kang, JH; Kim, KS | 1 |
| Fink, AL; Uversky, VN; Yamin, G | 1 |
| Kurup, PA; Kurup, RK | 1 |
| Blandini, F; Bono, G; Calandrella, D; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Riboldazzi, G; Samuele, A | 1 |
| Bennett, JP; Borland, MK; Keeney, PM; Parker, WD; Trimmer, PA | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Muhlack, S; Müller, T; Przuntek, H; Twiehaus, S; Welnic, J; Woitalla, D | 1 |
| Borutaite, V; Brown, GC | 1 |
| Giasson, BI; Hodara, R; Ischiropoulos, H; Lee, VM; Norris, EH; Trojanowski, JQ; Xu, S | 1 |
| Giasson, BI; Hodara, R; Ischiropoulos, H; Lee, VM; Lynch, DR; Mishizen-Eberz, AJ; Norris, EH; Trojanowski, JQ | 1 |
| Choi, DK; Heinecke, JW; Jackson-Lewis, V; Pennathur, S; Perier, C; Przedborski, S; Teismann, P; Tieu, K; Vila, M; Vonsattel, JP; Wu, DC | 1 |
| Bezard, E; Guo, S; Zhao, B | 1 |
| Bodner, N; Edridge, S; Fink, AL; Hong, DP; Kaylor, J; Yamin, G | 1 |
| Chen, JF; He, JC; Huang, QY; Shen, HY; Wang, Y | 1 |
| Abou-Sleiman, PM; Ahmadi, KR; Barker, R; Bhatia, KP; Casas, JP; Foltynie, T; Gandhi, S; Gibson, JM; Goldstein, DB; Healy, DG; Holton, JL; Lees, AJ; Lynch, T; Muqit, MM; Quinn, NP; Revesz, T; Wood, NW | 1 |
| Dalfó, E; Ferrer, I; Martinez, A; Muntané, G | 1 |
| Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Abe, T; Isobe, C; Kikuchi, T; Murata, T; Sato, C; Terayama, Y | 1 |
| Ametamey, SM; Blagoev, M; Hengerer, B; Hintermann, S; Honer, M; Schubiger, PA; Waldmeier, P | 1 |
| Becker, G; Gerlach, M; Lange, KW; Mecklinger, L; Naumann, M; Tucha, O; Walitza, S | 1 |
| Derenko, MV; Grzybowski, T; Malyarchuk, BA; Miścicka-Sliwka, D; Stopińska, K | 1 |
| Muhlack, S; Müller, T; Welnic, J | 1 |
| Bergman, O; Carmine Belin, A; Galter, D; Lind, C; Nissbrandt, H; Sydow, O; Westerlund, M | 1 |
| Agid, Y; Bonnet, AM; Borg, M; Brice, A; Broussolle, E; Damier, P; Destée, A; Durif, F; Dürr, A; Janin, S; Layet, V; Leclere, L; Lesage, S; Leutenegger, AL; Lohmann, E; Martinez, M; Penet, C; Pollak, P; Rasco, O; Thobois, S; Tison, F; Tranchan, C; Vérin, M; Viallet, F; Vidailhet, M | 1 |
| Ander, L; Kolf, K; Muhlack, S; Müller, T; Woitalla, D | 1 |
| Caidahl, K; Gramsbergen, JB; Larsen, TR; Roepstorff, P; Söderling, AS | 1 |
| Bird, TD; Edwards, KL; Factor, SA; Griffith, A; Higgins, DS; Hutter, CM; Kay, DM; Leis, BC; Montimurro, JS; Nutt, JG; Payami, H; Roberts, JW; Samii, A; Zabetian, CP | 1 |
| Chang, NS; Chen, ST; Chuang, JI; Hsu, LJ; Hsu, SY; Li, MY; Lin, SR; Lo, CP; Tsai, MS | 1 |
| Bergantino, E; Bisaglia, M; Bubacco, L; Mammi, S; Samorì, B; Tessari, I; Valle, F | 1 |
| Wurtman, RJ | 1 |
| Growdon, JH; Hefti, F; Logue, M; Melamed, E; Wurtman, RJ | 1 |
| Aguado, EG; de Yebenes, JG; Mena, MA | 1 |
| Hefti, F; Melamed, E; Wurtman, RJ | 1 |
| Beers, MF; Hurtig, H; Melvin, G; Scarpa, A; Stern, M | 1 |
| Botteri, A; Hamfelt, A; Söderhjelm, L | 1 |
| Asahara, K; Hirose, S; Imaizumi, M; Ishimitsu, T | 1 |
| Aguado, EG; Bazán, E; de Yébenes, JG; Gervas, JJ; Muradás, V | 1 |
| Fahn, S; Prasad, AL | 1 |
| Iizuka, R; Kondo, T; Matsuura, S; Nagatsu, T; Narabayashi, H; Sugimoto, T; Yamaguchi, T | 1 |
| Fahn, S; Reches, A | 1 |
| Riederer, P | 1 |
| Abe, T; Saheki, M; Takahashi, S; Tohgi, H; Tsukamoto, Y; Yamazaki, K | 1 |
| Bamberg, H; Böhme, V; Moser, A; Nobbe, F; Scholz, J; Vieregge, P | 1 |
| Chirakal, R; Firnau, G; Garnett, ES; Nahmias, C; Wahl, L | 1 |
| Aruoma, OI; Dexter, DT; Evans, PJ; Halliwell, B; Jenner, A; Jenner, P; Kaur, H; Lees, AJ; Marsden, DC; Spencer, JP | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Baraldo, M; Benetello, P; Furlanut, M; Hassan, E; Zara, G | 1 |
| Carter, JH; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, W | 1 |
| Cohen, G; DiRocco, A; Merchant, CA; Molinari, S; Moros, D; Mytilineou, C; Yahr, MD | 1 |
| Rinne, UK; Ruottinen, HM | 1 |
| Belakhlef, A; Chaly, T; Dahl, R; Dhawan, V; Eidelberg, D; Ishikawa, T; Mandel, F; Margouleff, C; Robeson, W | 1 |
| O'Connell, MT; Patsalos, PN; Quinn, NP; Tison, F | 1 |
| Hattori, Y; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Narabayashi, H; Tohgi, H; Tsukamoto, Y; Yamamoto, M; Yanagisawa, N; Yokochi, M | 1 |
| Antkiewicz-Michaluk, L; Krygowska-Wajs, A; Romańska, I; Szczudlik, A; Vetulani, J | 1 |
| Blandini, F; Desideri, S; Martignoni, E; Nappi, G; Pacchetti, C; Rivellini, D | 1 |
| Crevoisier, C; Dingemanse, J; Gasser, UE; Kleinbloesem, CH; Lankhaar, G | 1 |
| Good, PF; Hsu, A; Olanow, CW; Perl, DP; Werner, P | 1 |
| Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P | 1 |
| Arun, P; Kurup, PA; Leelamma, S; Ravikumar, A | 1 |
| Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M | 1 |
| Buchholz, J; Iacono, RP; Kuniyoshi, S; Liu, H; Schoonenberg, T | 1 |
| Furlanut, M; Wu, G | 1 |
| Blandini, F; Desideri, S; Godi, L; Mancini, F; Martignoni, E; Nappi, G; Pacchetti, C | 1 |
| Blandini, F; di Jeso, F; Martignoni, E; Nappi, G; Ricotti, R | 1 |
| Chen, JJ; Chirakal, R; Nahmias, C; Thompson, M; Wahl, LM | 1 |
| Heinecke, JW; Jackson-Lewis, V; Pennathur, S; Przedborski, S | 1 |
| Aoyama, K; Fujikawa, Y; Hayase, N; Kobayashi, S; Matsubara, K; Nagahiro, Y; Shimizu, K; Shiono, H; Umegae, N | 1 |
| Parada, A; Serrão, P; Soares-da-Silva, P | 1 |
| Carreras, MC; Cherñavsky, A; Gatto, EM; Poderoso, JJ; Riobó, NA; Rubio, A; Satz, ML | 1 |
| Arun, P; Deepadevi, KV; Kurup, PA; Manojkumar, V; Ravikumar, A | 1 |
| Mellick, GD; Silburn, PA | 1 |
| Chen, Q; Duda, JE; Giasson, BI; Hurtig, HI; Ischiropoulos, H; Lee, VM; Murray, IV; Souza, JM; Trojanowski, JQ | 1 |
| Blandini, F; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Samuele, A | 1 |
| Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ | 1 |
| Boveris, AD; Cadenas, E; Poderoso, JJ; Riobó, NA; Schöpfer, FJ | 1 |
| Fowler, B; Kuhn, W; Müller, T; Woitalla, D | 1 |
| Birkmayer, W; Jellinger, K; Rausch, WD; Riederer, P; Seemann, D | 1 |
| Carlsson, A | 1 |
| Deze, J; Völler, GW | 1 |
| Birkmayer, W; Danielczyk, W; Neumayer, E; Riederer, P | 2 |
| Berner, VP; Karobath, M; Scholtz, J | 1 |
| Cotzias, GC; Tang, LC | 1 |
| Hasegawa, S; Konagaya, Y; Maruyama, W; Mokuno, K; Nakahara, D; Naoi, M; Takahashi, A; Watanabe, H | 1 |
| Beal, MF; Bird, ED; Matson, WR; Milbury, P; Ogawa, T; Ryan, EA; Storey, E | 1 |
| Beal, MF; Bird, ED; Matson, WR; Milbury, P; Myers, RH; Ogawa, T; Saso, S | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, S; Tohgi, H | 2 |
| Cedarbaum, JM; Guttman, M; Leger, G | 1 |
| Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V | 1 |
| Lemoine, P; Mouret, J; Robelin, N; Sebert, P | 1 |
| Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 1 |
| Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Boomsma, F; Hovestadt, A; Man in't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Chen, QZ; Dong, YJ; Liu, BH; Shao, KS; Wang, YH; Xu, FH; Xu, HJ; Xu, JJ; Xu, JP; Zhu, SL | 1 |
| Allen, JG; Hardie, RJ; Lees, AJ; Malcolm, SL; Stern, GM | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Serrati, C | 1 |
| Gancher, ST; Merrick, D; Nutt, JG; Woodward, WR | 1 |
| Kondo, T; Nagatsu, T; Narabayashi, H; Sawada, M; Yamaguchi, T | 1 |
| Reches, A | 1 |
| Slevin, JT; Sparks, DL | 1 |
| Bermejo Pareja, F; de Yébenes, JG; Martinez-Martin, P; Muradas, V | 1 |
| Hirose, S; Ishimitsu, T | 1 |
| Martin, WE | 1 |
| Robins, AH | 1 |
| McGeer, PL | 1 |
| Corne, SJ; Hunter, DR; Sandler, M; Shaw, DM; Stephens, R; Stern, GM | 1 |
| Bates, D; Burton, JL; Goolamali, SK; Plummer, N; Shuster, S; Thody, AJ | 2 |
| Cotzias, GC; Gellene, R; Papavasiliou, PS | 1 |
| Birkmayer, W | 2 |
| Birkmayer, W; Mentasti, M | 1 |
| Arushanian, EB | 1 |
| Baker, AB; Martin, WE; Resch, JA | 1 |
| Axelrod, J; Weinshilboum, R | 1 |
| Granerus, AK; Jagenburg, R; Rödjer, S; Svanborg, A | 2 |
| Presthus, J | 1 |
| Boulton, AA; Wu, PH | 1 |
| Ambrozi, L; Birkmayer, W; Danielczyk, W; Neumayer, E; Riederer, P | 1 |
| Chase, TN; Colburn, RW; Kopin, IJ; Ng, LK | 1 |
| Tsubaki, T; Tsukada, Y; Yamada, K | 1 |
| Dinsmore, SR; Mrochek, JE; Ohrt, DW | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Koetsier, JC; Stoof, JC | 1 |
| Barbeau, A | 1 |
| Sandler, M | 1 |
| Andén, NE; Carlsson, A; Kerstell, J; Magnusson, T; Olsson, R; Roos, BE; Steen, B; Steg, G; Svanborg, A; Thieme, G; Werdinius, B | 1 |
| Goodwin, BL; Ruthven, CR; Sandler, M | 1 |
| Jung, E; McGeer, EG; McGeer, PL; Wada, JA | 1 |
| Cotzias, GC; Düby, S; Ginos, J; Papavasiliou, PS; Steck, A | 1 |
| Poirier, LJ | 1 |
| Bédard, P; Larochelle, L; Poirier, LJ | 1 |
| Fellman, JH; Joyce, JR; Strandholm, JJ | 1 |
| Beani, L; Bianchi, C; Cartei, M; Gomirato, G; Perfetti, C | 1 |
| Ericsson, AD; McCann, DS; Szpunar, WE | 1 |
| Bowers, MB; van Woert, MH | 1 |
| Ericsson, AD; Honos, E; McCann, DS | 1 |
| Chase, TN; Colburn, RW; Kopin, IJ; Ng, KY | 1 |
| Sakharova, AV; Stepanova, VG | 1 |
| Poskanzer, DC | 1 |
| Braham, J; Crispin, M; Golan, R; Levin, N; Sarova-Pinhas, I; Szeinberg, A | 1 |
16 review(s) available for tyrosine and Parkinson Disease
| Article | Year |
|---|---|
Src family kinases (SFKs): critical regulators of microglial homeostatic functions and neurodegeneration in Parkinson's and Alzheimer's diseases.
Topics: Alzheimer Disease; Humans; Microglia; Parkinson Disease; Protein-Tyrosine Kinases; src-Family Kinases; Tyrosine | 2022 |
3-Nitrotyrosine: a versatile oxidative stress biomarker for major neurodegenerative diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biomarkers; Humans; Huntington Disease; Parkinson Disease; Prion Diseases; Tyrosine | 2020 |
Lack of association between UCHL1 S18Y gene polymorphism and Parkinson's disease in the Asian population: a meta-analysis.
Topics: Asian People; Genetic Predisposition to Disease; Humans; Parkinson Disease; Polymorphism, Single Nucleotide; Serine; Tyrosine; Ubiquitin Thiolesterase | 2014 |
Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols.
Topics: Adenosine Triphosphate; Animals; Electron Transport Complex I; Humans; Iron-Sulfur Proteins; Macrophages; Mitochondria; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrosation; Nitroso Compounds; Parkinson Disease; Peroxynitrous Acid; Reactive Nitrogen Species; Tyrosine | 2004 |
Effects of foods and nutrients on brain neurotransmitters.
Topics: Amino Acids; Animals; Biological Transport, Active; Brain; Choline; Dopamine; Humans; Kinetics; Neurons; Neurotransmitter Agents; Norepinephrine; Nutritional Physiological Phenomena; Parkinson Disease; Prolactin; Serotonin; Tryptophan; Tyrosine | 1984 |
Monoamine precursors and analogues.
Topics: 5-Hydroxytryptophan; Animals; Biogenic Amines; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Drug Interactions; Drug Synergism; Humans; Levodopa; Mice; Parkinson Disease; Rats; Receptors, Drug; Stimulation, Chemical; Tremor; Tryptophan; Tyrosine | 1975 |
[Basis, clinical picture and therapy of diseases of the extrapyramidal-motoric system (EPMS)].
Topics: Acetylcholine; Athetosis; Basal Ganglia Diseases; Catecholamines; Chorea; Dopamine; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Hyperkinesis; Myoclonus; Parkinson Disease; Tremor; Tyrosine | 1975 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodopa; Locus Coeruleus; Myocardium; Norepinephrine; Pargyline; Parkinson Disease; Serine; Stereoisomerism; Tyrosine | 1985 |
The importance of monoamine metabolism for the pathology of the extrapyramidal system.
Topics: Aged; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catechol Oxidase; Catecholamines; Chorea; Dihydroxyphenylalanine; Dopamine; Humans; Kinetics; Methyltyrosines; Middle Aged; NAD; Parkinson Disease; Rats; Tritium; Tyrosine | 1969 |
[The role of dopamine in the physiology and pathology of the basal ganglia].
Topics: Basal Ganglia; Brain; Caudate Nucleus; Chlorpromazine; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Globus Pallidus; Haloperidol; Histocytochemistry; Humans; Hyperkinesis; Microscopy, Electron; Neurons; Norepinephrine; Parkinson Disease; Substantia Nigra; Synaptic Transmission; Tranquilizing Agents; Tritium; Tyrosine | 1972 |
Catecholamines.
Topics: Adrenal Medulla; Affective Symptoms; Animals; Brain; Catechol O-Methyltransferase; Catecholamines; Dihydroxyphenylalanine; Dopamine beta-Hydroxylase; Humans; Hypertension; Methyldopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Endings; Neurons; Parkinson Disease; Receptors, Drug; Sympathetic Nervous System; Sympathomimetics; Synaptic Transmission; Tyrosine; Tyrosine 3-Monooxygenase | 1972 |
[Other trials with drug therapy in parkinsonism].
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Dihydroxyphenylalanine; Disulfiram; Drug Evaluation; Drug Therapy, Combination; Humans; Imipramine; Methyldopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Rats; Serine; Time Factors; Tryptophan; Tyrosine | 1973 |
[Biochemical aspects of human behaviour (author's transl)].
Topics: Animals; Athetosis; Behavior; Behavior, Animal; Biogenic Amines; Brain; Brain Chemistry; Catecholamines; Chorea; Depression; Dopamine; Humans; Hydroxyindoleacetic Acid; Hyperkinesis; Monoamine Oxidase; Motor Activity; Parkinson Disease; Serotonin; Sexual Behavior; Tyrosine; Vanilmandelic Acid | 1973 |
Dopamine and dopamine metabolites in Parkinson's disease-a review.
Topics: Brain Chemistry; Dopamine; Humans; Movement Disorders; Parkinson Disease; Phenylacetates; Tryptophan; Tyrosine | 1968 |
Biosynthesis and metabolism of the catecholamines.
Topics: Brain; Catecholamines; Dihydroxyphenylalanine; Dopa Decarboxylase; Epinephrine; Female; Glycols; Isoenzymes; Monoamine Oxidase; Norepinephrine; Parkinson Disease; Tyrosine; Uterus | 1970 |
Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
Topics: Animals; Brain; Choline; Chronic Disease; Dihydroxyphenylalanine; Drug Synergism; Humans; Manganese Poisoning; Melatonin; Methionine; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenylalanine; Poisoning; Pyridoxine; Tryptophan; Tyrosine | 1971 |
29 trial(s) available for tyrosine and Parkinson Disease
| Article | Year |
|---|---|
Effect of
Topics: Constipation; Gastrointestinal Microbiome; Humans; Lacticaseibacillus; Lacticaseibacillus casei; Lacticaseibacillus paracasei; Neurodegenerative Diseases; Parkinson Disease; Probiotics; Tyrosine | 2023 |
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors; Tyrosine | 2009 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechols; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Pilot Projects; Self Report; Single-Blind Method; Sweden; Tolcapone; Tyrosine | 2012 |
Hypothalamic digoxin-mediated model for Parkinson's disease.
Topics: Aged; Digoxin; Dolichols; Enzyme Inhibitors; Erythrocytes; Female; Glycoconjugates; Glycosaminoglycans; Humans; Hydroxymethylglutaryl CoA Reductases; Hypothalamus; Male; Membrane Proteins; Middle Aged; Models, Biological; Neurons; Parkinson Disease; Polyisoprenyl Phosphates; Sodium-Potassium-Exchanging ATPase; Tryptophan; Tyrosine; Ubiquinone | 2003 |
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Biological Availability; Dihydroxyphenylalanine; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Tyrosine | 2004 |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Tyrosine | 2006 |
Brain dopamine and kinematics of graphomotor functions.
Topics: Adult; Aged; Antiparkinson Agents; Biomechanical Phenomena; Brain; Computer Graphics; Cross-Over Studies; Dopamine; Dopamine Agonists; Double-Blind Method; Echoencephalography; Female; Handwriting; Humans; Male; Middle Aged; Parkinson Disease; Phenylalanine; Reaction Time; Reference Values; Signal Processing, Computer-Assisted; Substantia Nigra; Synaptic Transmission; Tyrosine | 2006 |
Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Down-Regulation; Enzyme Inhibitors; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Levodopa; Male; Middle Aged; Neural Pathways; Parkinson Disease; Raphe Nuclei; Serotonin; Tyrosine | 2007 |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2007 |
Human transplacental transfer of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Female; Fetus; Homovanillic Acid; Humans; Levodopa; Maternal-Fetal Exchange; Parkinson Disease; Pregnancy; Tyrosine | 1995 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Double-Blind Method; Enzyme Inhibitors; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 1996 |
Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Area Under Curve; Drug Monitoring; Half-Life; Humans; Levodopa; Microdialysis; Parkinson Disease; Tyrosine | 1996 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1997 |
Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.
Topics: Adult; Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dementia; Female; Homovanillic Acid; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Tyrosine | 1997 |
Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Cross-Over Studies; Delayed-Action Preparations; Female; Food; Humans; Levodopa; Male; Parkinson Disease; Tablets; Tyrosine | 1998 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Time Factors; Tolcapone; Tyrosine | 1999 |
Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: an application of the Dixon equation.
Topics: Aged; Drug Interactions; Female; Humans; Levodopa; Male; Models, Statistical; Parkinson Disease; Tyrosine | 1999 |
Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
Topics: Antiparkinson Agents; Biomarkers; Blood Platelets; Dopamine; Female; Gentisates; Humans; Hydroxybenzoates; Hydroxyl Radical; In Vitro Techniques; Levodopa; Linear Models; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Sodium Salicylate; Superoxide Dismutase; Tyrosine | 1999 |
Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection.
Topics: Adult; Antiparkinson Agents; Blood Platelets; Chromatography, High Pressure Liquid; Electrochemistry; Female; Humans; Hydroxybenzoates; Hydroxyl Radical; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1999 |
Tetrahydrobiopterin and Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Fasting; Half-Life; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Reference Values; Tablets; Tyrosine | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1989 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
Topics: Absorption; Administration, Oral; Adult; Carboxy-Lyases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Intravenous; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1986 |
Metatyrosine in the treatment of parkinsonism.
Topics: Animals; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Intestinal Absorption; Mice; Middle Aged; Parkinson Disease; Rats; Tyrosine | 1972 |
Modification of Parkinsonism--chronic treatment with L-dopa.
Topics: Adult; Aged; Agranulocytosis; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Urea Nitrogen; Blood-Brain Barrier; Chronic Disease; Dihydroxyphenylalanine; Dopamine; Feeding and Eating Disorders; Female; Humans; Huntington Disease; Male; Manganese; Mental Processes; Methyldopa; Middle Aged; Movement Disorders; Nausea; Neurologic Manifestations; Parkinson Disease; Phenylacetates; Placebos; Thyroid Function Tests; Tyrosine; Vomiting | 1969 |
Oral L-dopa treatment of parkinsonism.
Topics: Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamine; Humans; Parkinson Disease; Phenylacetates; Physical Therapy Modalities; Placebos; Tyrosine | 1970 |
168 other study(ies) available for tyrosine and Parkinson Disease
| Article | Year |
|---|---|
Structural Basis for Dityrosine-Mediated Inhibition of α-Synuclein Fibrillization.
Topics: alpha-Synuclein; Amyloid; Humans; Parkinson Disease; Tyrosine | 2022 |
DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers.
Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Humans; Mice; Parkinson Disease; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase | 2022 |
Nonreceptor Tyrosine Kinase c-Abl-Mediated PHB2 Phosphorylation Aggravates Mitophagy Disorder in Parkinson's Disease Model.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Humans; Mice; Mitophagy; Neuroblastoma; Parkinson Disease; Phosphorylation; Prohibitins; TYK2 Kinase; Tyrosine | 2022 |
Tyrosine Metabolism Pathway Is Downregulated in Dopaminergic Neurons with LRRK2 Overexpression in
Topics: Animals; Dopaminergic Neurons; Drosophila; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Nerve Degeneration; Parkinson Disease; Tyrosine | 2023 |
Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Flavones; Gait; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase | 2020 |
Role of Tyr-39 for the Structural Features of α-Synuclein and for the Interaction with a Strong Modulator of Its Amyloid Assembly.
Topics: alpha-Synuclein; Amyloid; Humans; Intrinsically Disordered Proteins; Parkinson Disease; Point Mutation; Protein Conformation; Tyrosine | 2020 |
There may be no significant increase of cerebrospinal fluid tyrosine levels in patients with Parkinson's disease.
Topics: Humans; Parkinson Disease; Tyrosine | 2021 |
Megadalton-sized Dityrosine Aggregates of α-Synuclein Retain High Degrees of Structural Disorder and Internal Dynamics.
Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Cytochromes c; Humans; Magnetic Resonance Spectroscopy; Mitochondria; Neurons; Oxidative Stress; Parkinson Disease; Protein Aggregates; Protein Conformation; Reactive Oxygen Species; Tyrosine | 2020 |
Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease: a pilot study.
Topics: Chemokine CX3CL1; Disabled Persons; Humans; Motor Disorders; Parkinson Disease; Pilot Projects; Severity of Illness Index; Tyrosine | 2022 |
Monitoring of a progressive functional dopaminergic deficit in the A53T-AAV synuclein rats by combining 6-[
Topics: alpha-Synuclein; Animals; Dependovirus; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Fluorine Radioisotopes; Male; Motor Activity; Parkinson Disease; Phosphorylation; Positron-Emission Tomography; Protein Aggregates; Rats, Sprague-Dawley; Synucleinopathies; Tyrosine | 2021 |
LRRK2 mediated Rab8a phosphorylation promotes lipid storage.
Topics: 3T3-L1 Cells; Animals; Cell Cycle Proteins; Humans; Lipid Droplets; Lipid Metabolism; Membrane Proteins; Membrane Transport Proteins; Mice; Mutation; Parkinson Disease; rab GTP-Binding Proteins; Transcription Factor TFIIIA; Tyrosine | 2018 |
Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding.
Topics: alpha-Synuclein; Autopsy; Binding Sites; Brain; Humans; Parkinson Disease; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Serine; Single-Domain Antibodies; Tyrosine | 2018 |
2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Behavior, Animal; Cyclooxygenase 2; Cytokines; Disease Models, Animal; DNA Damage; Dopamine Plasma Membrane Transport Proteins; Inflammation; Mice, Inbred C57BL; Microglia; NF-E2-Related Factor 2; Nitric Oxide Synthase Type II; Nitrosative Stress; Oxazoles; Oxidative Stress; Parkinson Disease; Poly Adenosine Diphosphate Ribose; Transcription Factor RelA; Tyrosine; Tyrosine 3-Monooxygenase | 2018 |
Synthesis and biological evaluation of clovamide analogues with catechol functionality as potent Parkinson's disease agents in vitro and in vivo.
Topics: Apoptosis; Catechols; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Structure-Activity Relationship; Tyrosine | 2019 |
Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients.
Topics: Adult; Aged; Biogenic Amines; Biomarkers; Cross-Sectional Studies; Disease Progression; Early Diagnosis; Female; Humans; Male; Middle Aged; Norepinephrine; Parkinson Disease; Serotonin; Synephrine; Tyramine; Tyrosine | 2019 |
May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of sporadic Parkinson's disease?
Topics: Albumins; alpha-Synuclein; Biomarkers; Humans; Mass Spectrometry; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Tyrosine | 2013 |
Possible chemical initiators of cognitive dysfunction in phenylketonuria, Parkinson's disease and Alzheimer's disease.
Topics: Alzheimer Disease; Catechols; Cognition Disorders; Humans; Metabolic Networks and Pathways; Methionine; Models, Biological; Molecular Structure; Oxidative Stress; Parkinson Disease; Phenylalanine; Phenylketonurias; Tyrosine | 2013 |
Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.
Topics: Animals; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Inflammation; Lythraceae; Male; Mitochondrial Diseases; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinson Disease; Rats; Rats, Inbred Lew; Rotenone; Substantia Nigra; Tyrosine | 2014 |
Electrochemical analysis of the fibrillation of Parkinson's disease α-synuclein.
Topics: alpha-Synuclein; Amyloid; Electrochemical Techniques; Electrodes; Graphite; Humans; Oxidation-Reduction; Parkinson Disease; Protein Folding; Proteostasis Deficiencies; Tyrosine | 2014 |
A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tyrosine | 2014 |
May the thyroid gland and thyroperoxidase participate in nitrosylation of serum proteins and sporadic Parkinson's disease?
Topics: Aged; Case-Control Studies; Female; Humans; Iodide Peroxidase; Male; Middle Aged; Parkinson Disease; Protein Processing, Post-Translational; Thyroid Gland; Tyrosine | 2014 |
LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biomarkers; Chromatography, Liquid; Drosophila melanogaster; Fatty Acids; Histidine; Humans; Kynurenine; Mass Spectrometry; Metabolomics; Nucleotides; Parkinson Disease; Phenotype; Phenylalanine; Steroids; Tryptophan; Tyrosine | 2015 |
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.
Topics: Amidines; Animals; Antibodies, Monoclonal; Astrocytes; Benzylamines; Cell Count; Cells, Cultured; Dopaminergic Neurons; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Mesencephalon; Microglia; Neuroprotective Agents; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinson Disease; Picolines; Primary Cell Culture; Rats, Wistar; Thiophenes; Tyrosine; Tyrosine 3-Monooxygenase | 2015 |
Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
Topics: Animals; Cell Fractionation; Cells, Cultured; Cytokines; Disease Models, Animal; Encephalitis; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Nitric Oxide; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Kinase C-delta; Proto-Oncogene Proteins c-fyn; Tumor Necrosis Factor-alpha; Tyrosine; Tyrosine 3-Monooxygenase | 2015 |
The novel mechanism of rotenone-induced α-synuclein phosphorylation via reduced protein phosphatase 2A activity.
Topics: alpha-Synuclein; Animals; Calmodulin; Cerebral Cortex; Down-Regulation; Humans; Mesencephalon; Neurons; Parkinson Disease; Phosphorylation; Protein Aggregates; Protein Phosphatase 2; Rats; Rotenone; src-Family Kinases; Tyrosine | 2016 |
Serum Tyrosine-to-Phenylalanine Ratio is Low in Parkinson's Disease.
Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenylalanine; Sweat; Tyrosine | 2016 |
C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Autophagy; Globins; Humans; Lewy Bodies; Nerve Tissue Proteins; Neuroglobin; Oxidation-Reduction; Parkinson Disease; Phosphorylation; Proteasome Endopeptidase Complex; Saccharomyces cerevisiae; Serine; Tyrosine | 2016 |
The involvement of dityrosine crosslinking in α-synuclein assembly and deposition in Lewy Bodies in Parkinson's disease.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Amino Acid Sequence; Brain; Copper; Dimerization; Electrophoresis, Polyacrylamide Gel; Humans; Lewy Bodies; Male; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Recombinant Proteins; Tandem Mass Spectrometry; Tyrosine | 2016 |
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides; Dopamine Agents; Electrochemical Techniques; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors; Tyrosine | 2017 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radioisotopes; Image Processing, Computer-Assisted; Male; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Presynaptic; Stereotyped Behavior; Tyrosine | 2017 |
Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties.
Topics: Alanine; alpha-Synuclein; Amino Acid Substitution; Amyloid; Circular Dichroism; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Mutation, Missense; Parkinson Disease; Protein Folding; Protein Structure, Secondary; Recombinant Proteins; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Tyrosine | 2008 |
Alpha-Synuclein conformation affects its tyrosine-dependent oxidative aggregation.
Topics: alpha-Synuclein; Cytochromes c; Humans; Hydrogen Peroxide; Molecular Conformation; Mutation; Oxidative Stress; Oxygen; Parkinson Disease; Protein Binding; Protein Denaturation; Protein Structure, Tertiary; Recombinant Proteins; Tyrosine | 2008 |
Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Iodobenzylguanidine; Animals; Dopamine; Mice; Myocardium; Neostriatum; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Lewy Bodies; Mass Spectrometry; Models, Biological; Monoamine Oxidase; Nitrates; Oxidative Stress; Parkinson Disease; PC12 Cells; Rats; Tyrosine | 2009 |
Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.
Topics: Aging; alpha-Synuclein; Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Humans; Neurons; Parkinson Disease; Phosphorylation; Serine; Tyrosine | 2009 |
Electroenzymatic synthesis of l-DOPA.
Topics: Bioreactors; Electrochemical Techniques; Electrodes; Enzymes, Immobilized; Kinetics; Levodopa; Linear Models; Monophenol Monooxygenase; Parkinson Disease; Tyrosine | 2010 |
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.
Topics: alpha-Synuclein; Animals; Dopamine; Humans; In Vitro Techniques; Lentivirus; Mice; Mice, Transgenic; Mutagenesis; Neurotransmitter Agents; Parkinson Disease; Phosphorylation; Protein Phosphatase 2; Serine; Tyrosine; Tyrosine 3-Monooxygenase | 2010 |
Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
Topics: Aged; alpha-Synuclein; Antiparkinson Agents; Autophagy; Female; Gene Frequency; Genotype; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Promoter Regions, Genetic; Reactive Oxygen Species; Sex Distribution; Tyrosine | 2010 |
Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Curcumin; Diet; Electron Transport Complex I; Esters; Flavonoids; Glutamates; Mice; Mitochondria; Mitochondrial Proteins; Mitochondrial Swelling; Parkinson Disease; Peroxynitrous Acid; Phenols; Polyphenols; Protective Agents; Tyrosine | 2011 |
Common pathogenic pathways in melanoma and Parkinson disease.
Topics: Brain Neoplasms; Group VI Phospholipases A2; Humans; Levodopa; Melanoma; Neural Pathways; Parkinson Disease; Tyrosine | 2010 |
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Flurbiprofen; Humans; Inflammation; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidoreductases; Parkinson Disease; Rotarod Performance Test; Substantia Nigra; Tyrosine | 2010 |
Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.
Topics: Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tyrosine | 2011 |
Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Carbidopa; Dipeptides; Female; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Tyrosine | 2011 |
Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding.
Topics: Allosteric Regulation; alpha-Synuclein; Humans; Hydrodynamics; Lipid Bilayers; Membrane Lipids; Mutation; Nitrates; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Protein Binding; Protein Structure, Secondary; Tyrosine | 2011 |
A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Topics: Aged; Brain; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tomography, Emission-Computed; Tyrosine | 2011 |
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Topics: Aged; alpha-Synuclein; Biomarkers; Colon; Enteric Nervous System; Female; Humans; Male; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine | 2012 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.
Topics: Acute-Phase Proteins; Aged; alpha-Synuclein; Biomarkers; Carrier Proteins; Endotoxins; Escherichia coli; Escherichia coli Infections; Female; Humans; Immunoenzyme Techniques; Intestinal Mucosa; Intestines; Male; Membrane Glycoproteins; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Permeability; Sucrose; Tyrosine | 2011 |
A Korean Parkinson's disease family with the LRRK2 p.Tyr1699Cys mutation showing clinical heterogeneity.
Topics: Age of Onset; Aged; Cysteine; DNA Mutational Analysis; Family Health; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Parkinson Disease; Protein Serine-Threonine Kinases; Republic of Korea; Tyrosine | 2012 |
Phosphorylation of α-synuclein is crucial in compensating for proteasomal dysfunction.
Topics: alpha-Synuclein; Animals; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Focal Adhesion Protein-Tyrosine Kinases; HSC70 Heat-Shock Proteins; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Proteasome Endopeptidase Complex; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Tyrosine | 2012 |
Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Topics: alpha-Synuclein; Amino Acid Sequence; Binding Sites; Copper; Cross-Linking Reagents; Fluorescence; Humans; Iron; Lead; Metals; Models, Molecular; Molecular Sequence Data; Neuropeptides; Parkinson Disease; Phosphorylation; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tyrosine | 2011 |
Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Wistar; Tyrosine | 2012 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinations; Female; Gels; Germany; Humans; Infusion Pumps; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Tyrosine | 2013 |
Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Oxidopamine; Parkinson Disease; PC12 Cells; Phosphorylation; Protein Tyrosine Phosphatases; Quinpirole; Rats; Receptors, Dopamine D2; Sympatholytics; Tyrosine; Vanadates | 2002 |
Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.
Topics: alpha-Synuclein; Amino Acid Substitution; Chromatography, High Pressure Liquid; Cross-Linking Reagents; Dimerization; Humans; Hydrogen-Ion Concentration; Light; Nerve Tissue Proteins; Osmolar Concentration; Osmotic Pressure; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Protein Isoforms; Scattering, Radiation; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Ultraviolet; Synucleins; Temperature; Tyrosine | 2003 |
Enhanced oligomerization of the alpha-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system.
Topics: alpha-Synuclein; Amino Acid Substitution; Anserine; Antioxidants; Antiparkinson Agents; Biopolymers; Carnosine; Chelating Agents; Codon; Copper; Edetic Acid; Free Radical Scavengers; Humans; Hydrogen Peroxide; Hydroxyl Radical; Isopropyl Thiogalactoside; Lewy Bodies; Mutagenesis, Site-Directed; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Phenylmethylsulfonyl Fluoride; Point Mutation; Resins, Synthetic; Spin Labels; Superoxide Dismutase; Superoxide Dismutase-1; Synucleins; Tyrosine | 2003 |
Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers.
Topics: alpha-Synuclein; Humans; Kinetics; Nerve Tissue Proteins; Parkinson Disease; Solubility; Synucleins; Tetranitromethane; Tyrosine | 2003 |
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Benzophenones; Blood Platelets; Catechols; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Retrospective Studies; Sex Characteristics; Tolcapone; Tyrosine; Up-Regulation | 2003 |
Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies.
Topics: Aged; alpha-Synuclein; Blotting, Western; Carrier Proteins; Case-Control Studies; Cell Line; Cysteine Endopeptidases; Cytochromes c; DNA, Mitochondrial; Electron Transport Complex I; Female; Humans; Immunohistochemistry; Lewy Bodies; Male; Microscopy, Confocal; Microscopy, Electron; Middle Aged; Multienzyme Complexes; Nerve Tissue Proteins; Neuroblastoma; Neurofilament Proteins; Neurons; Parkinson Disease; Precipitin Tests; Proteasome Endopeptidase Complex; Staining and Labeling; Synucleins; Transgenes; Tubulin; Tyrosine; Ubiquitin; Ubiquitin-Protein Ligases | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Benzylamines; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Locus Coeruleus; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Statistics, Nonparametric; Tyrosine | 2004 |
Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.
Topics: alpha-Synuclein; Amino Acid Motifs; Circular Dichroism; DNA, Complementary; Dopamine; Histidine; Humans; Indolequinones; Methionine; Microscopy, Atomic Force; Microscopy, Electron; Mutagenesis; Mutation; Nerve Tissue Proteins; Oxidative Stress; Oxygen; Parkinson Disease; Peptides; Protein Conformation; Protein Structure, Secondary; Recombinant Proteins; Spectroscopy, Fourier Transform Infrared; Synucleins; Time Factors; Tyrosine | 2005 |
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.
Topics: alpha-Synuclein; Calpain; Chymotrypsin; Humans; Hydrolysis; Microscopy, Immunoelectron; Nerve Degeneration; Nerve Tissue Proteins; Nitrates; Parkinson Disease; Peptide Fragments; Peroxynitrous Acid; Recombinant Proteins; Solubility; Synucleins; Tyrosine | 2005 |
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amyotrophic Lateral Sclerosis; Animals; Brain; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Enzyme Induction; Humans; Huntington Disease; Hypochlorous Acid; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Tissue Proteins; Neurons; Oxidative Stress; Parkinson Disease; Parkinsonian Disorders; Peroxidase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tyrosine | 2005 |
Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway.
Topics: Annexin A5; Apoptosis; Blotting, Western; Calcium; Cell Line, Tumor; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Flavonoids; Flow Cytometry; Free Radicals; Guanosine Triphosphate; Humans; Membrane Potentials; Mitochondria; Models, Biological; Neurons; Nitric Oxide; Oxidopamine; Oxygen; Parkinson Disease; Phenols; Polyphenols; Quinones; Reactive Oxygen Species; Tea; Tetrazolium Salts; Thiazoles; Time Factors; Tyrosine | 2005 |
Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein.
Topics: alpha-Synuclein; Anilino Naphthalenesulfonates; Benzothiazoles; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Humans; Mutagenesis, Site-Directed; Nerve Tissue Proteins; Parkinson Disease; Protein Structure, Secondary; Spectroscopy, Fourier Transform Infrared; Synucleins; Thiazoles; Tryptophan; Tyrosine | 2005 |
Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzoquinones; Blotting, Western; Brain; Cell Death; Cell Nucleus; Cytosol; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Agents; Enzyme Inhibitors; Heat Shock Transcription Factors; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Immunohistochemistry; Lactams, Macrocyclic; Male; Mice; Mice, Inbred C57BL; Models, Biological; Molecular Chaperones; Neoplasm Proteins; Neurons; Neurotoxins; Parkinson Disease; Quinones; Time Factors; Transcription Factors; Tyrosine; Tyrosine 3-Monooxygenase | 2005 |
UCHL-1 is not a Parkinson's disease susceptibility gene.
Topics: Case-Control Studies; Confidence Intervals; Female; Genotype; Humans; Linkage Disequilibrium; Male; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Parkinson Disease; Polymorphism, Genetic; Serine; Tyrosine; Ubiquitin Thiolesterase | 2006 |
Abnormal alpha-synuclein solubility, aggregation and nitration in the frontal cortex in Pick's disease.
Topics: Aged; alpha-Synuclein; Blotting, Western; Case-Control Studies; Female; Frontal Lobe; Humans; Immunohistochemistry; Male; Molecular Weight; Parkinson Disease; Pick Disease of the Brain; Postmortem Changes; Tyrosine | 2006 |
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, High Pressure Liquid; Ergolines; Female; Free Radical Scavengers; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Peroxynitrous Acid; Tyrosine | 2006 |
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Male; Mice; Mice, Inbred C57BL; Neurotransmitter Agents; Nortropanes; Parkinson Disease; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Substantia Nigra; Synaptic Transmission; Tyrosine | 2006 |
Optimization of the Y831C mutation detection in human DNA polymerase gamma by allelic discrimination assay.
Topics: Cysteine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Gene Frequency; Genetic Techniques; Humans; Mitochondrial Diseases; Parkinson Disease; Peripheral Nervous System Diseases; Point Mutation; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Tyrosine | 2006 |
S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden.
Topics: DNA Mutational Analysis; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Mutation; Odds Ratio; Parkinson Disease; Serine; Sweden; Tyrosine; Ubiquitin Thiolesterase | 2007 |
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Europe; Exons; Female; Histidine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Mutation; Parkinson Disease; Protein Serine-Threonine Kinases; Serine; Threonine; Tyrosine | 2007 |
Nitration of soluble proteins in organotypic culture models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Mice; Mice, Inbred C57BL; Neurochemistry; Neurotoxins; Nitric Oxide Donors; Nitric Oxide Synthase; Nitro Compounds; Organ Culture Techniques; Oxidative Stress; Parkinson Disease; Proteins; Pterins; Reactive Nitrogen Species; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2008 |
L-tyrosine. Monograph.
Topics: Attention Deficit Disorder with Hyperactivity; Depression; Food-Drug Interactions; Humans; Narcolepsy; Parkinson Disease; Phenylketonurias; Stress, Physiological; Tyrosine | 2007 |
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Odds Ratio; Parkinson Disease; Polymorphism, Genetic; Serine; Tyrosine; Ubiquitin Thiolesterase | 2008 |
MPP+-induced neuronal death in rats involves tyrosine 33 phosphorylation of WW domain-containing oxidoreductase WOX1.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Death; Cell Line, Tumor; Humans; Male; Neurons; Oxidoreductases; Parkinson Disease; Phosphorylation; Rats; Rats, Sprague-Dawley; Tumor Suppressor Proteins; Tyrosine; WW Domain-Containing Oxidoreductase | 2008 |
The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease.
Topics: alpha-Synuclein; Circular Dichroism; Cytosol; Dopamine; Humans; Models, Biological; Monophenol Monooxygenase; Mutation; Oxygen; Parkinson Disease; Quinones; Reactive Oxygen Species; Spectrophotometry, Ultraviolet; Time Factors; Tyrosine | 2008 |
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetates; Probenecid; Tyrosine | 1982 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; Dihydroxyphenylalanine; Electrochemistry; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphenylglycol; Parkinson Disease; Phenylacetates; Subarachnoid Hemorrhage; Tryptophan; Tyrosine | 1984 |
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovanillic Acid; Male; Parkinson Disease; Rats; Substantia Nigra; Synaptic Transmission; Tyrosine | 1980 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
Topics: Adult; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Epinephrine; Humans; Levodopa; Male; Methyltyrosines; Norepinephrine; Parkinson Disease; Tyrosine | 1984 |
Pyridoxal phosphate, tryptophan, and tyrosine in blood and cerebrospinal fluid in elderly patients.
Topics: Adult; Age Factors; Aged; Humans; Hydrocephalus; Middle Aged; Parkinson Disease; Pyridoxal Phosphate; Tryptophan; Tyrosine | 1984 |
The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Dopamine; Humans; Levodopa; Methyltyrosines; Parkinson Disease; Tyrosine | 1984 |
Effects of 3-OM-dopa on monoamine metabolism in rat brain.
Topics: alpha-Methyltyrosine; Animals; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Dopamine; Levodopa; Male; Methyltyrosines; Norepinephrine; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1983 |
A semiautomated method for the rapid determination of dopa: comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients.
Topics: Autoanalysis; Dihydroxyphenylalanine; Erythrocytes; Humans; Levodopa; Methyltyrosines; Parkinson Disease; Spectrometry, Fluorescence; Tyrosine | 1982 |
Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease.
Topics: Administration, Oral; Adrenal Glands; Alanine; Animals; Biopterins; Corpus Striatum; Humans; Injections, Intraperitoneal; Liver; Male; Parkinson Disease; Pteridines; Rats; Rats, Inbred Strains; Time Factors; Tyrosine | 1983 |
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Homovanillic Acid; Levodopa; Male; Methyltyrosines; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1982 |
L-dopa competes with tyrosine and tryptophan for human brain uptake.
Topics: Aged; Benserazide; Blood-Brain Barrier; Brain; Female; Humans; Levodopa; Male; Parkinson Disease; Tryptophan; Tyrosine | 1980 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1995 |
Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease.
Topics: Adult; Aged; Cerebrospinal Fluid Proteins; Dopamine; Female; Homovanillic Acid; Humans; Isoquinolines; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Tetrahydroisoquinolines; Tyrosine | 1995 |
A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain.
Topics: Adolescent; Adult; Aromatic-L-Amino-Acid Decarboxylases; Blood-Brain Barrier; Brain; Carbidopa; Corpus Striatum; Dopamine; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Male; Parkinson Disease; Radionuclide Imaging; Reference Values; Tyrosine | 1995 |
Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease.
Topics: Brain Chemistry; Catalysis; Copper; DNA; DNA Damage; Dopamine; Humans; Hydrogen Peroxide; Iron; Levodopa; Oxidation-Reduction; Parkinson Disease; Tyrosine | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Topics: Adult; Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Chromatography, High Pressure Liquid; Corpus Striatum; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Fluorine Radioisotopes; Humans; Kinetics; Male; Middle Aged; Nitriles; Occipital Lobe; Parkinson Disease; Quality Control; Sensitivity and Specificity; Tomography, Emission-Computed; Tyrosine | 1996 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
Topics: Adult; Aged; Antiparkinson Agents; Blood Platelets; Chromatography, High Pressure Liquid; Electrochemistry; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1997 |
Protein nitration in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Humans; Immunohistochemistry; Lewy Bodies; Middle Aged; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine | 1998 |
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catecholamines; Female; Hallucinations; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Isoquinolines; Levodopa; Male; Parkinson Disease; Reference Values; Regression Analysis; Tyrosine | 1996 |
Endogenous alkaloids in the brain of rats loaded with tyrosine/tryptophan & in the serum of patients of neurodegenerative & psychiatric disorders.
Topics: Alkaloids; Animals; Bipolar Disorder; Brain; Chromatography, High Pressure Liquid; Epilepsy; Female; Humans; Parkinson Disease; Rats; Rats, Sprague-Dawley; Tryptophan; Tyrosine | 1998 |
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Progression; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1999 |
The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration.
Topics: Antiparkinson Agents; Brain; Carbidopa; Dopamine; Fluorine Radioisotopes; Humans; Parkinson Disease; Time Factors; Tomography, Emission-Computed; Tyrosine | 1999 |
Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain; Chelating Agents; Dopamine Agents; Free Radicals; Gas Chromatography-Mass Spectrometry; Male; Mice; Mice, Inbred C57BL; Nitrates; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Pentetic Acid; Tissue Distribution; Tyrosine | 1999 |
Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases.
Topics: Adult; Aged; Alzheimer Disease; Antibodies; Biomarkers; Female; Humans; Male; Middle Aged; Nitrates; Nitrogen; Oxidative Stress; Parkinson Disease; Precipitin Tests; Superoxide Dismutase; Tyrosine | 2000 |
The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Kidney; Liver; Male; Neurons; Parkinson Disease; Rats; Tyrosine | 2000 |
Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease.
Topics: Blotting, Western; Enzyme Induction; Female; Humans; Hydrogen Peroxide; Male; Middle Aged; Neutrophils; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrophotometry; Tyrosine | 2000 |
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders.
Topics: Adult; Biogenic Monoamines; Brain Diseases; Brain Neoplasms; Digoxin; Epilepsy, Generalized; Erythrocytes; Fatty Acids, Nonesterified; Female; Glioma; Glycine Agents; Humans; Hydroxymethylglutaryl CoA Reductases; Kynurenic Acid; Magnesium; Male; Microvascular Angina; Middle Aged; Morphine; Narcotics; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinolinic Acid; Schizophrenia; Serum Albumin; Sodium-Potassium-Exchanging ATPase; Strychnine; Tryptophan; Tyrosine; Ubiquinone | 2000 |
The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Case-Control Studies; Electrophoresis, Agar Gel; Female; Genotype; Humans; Male; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Polymorphism, Genetic; Serine; Thiolester Hydrolases; Tyrosine; Ubiquitin Thiolesterase | 2000 |
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.
Topics: alpha-Synuclein; Alzheimer Disease; Antibodies, Monoclonal; Blotting, Western; Brain; Brain Chemistry; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Lewy Bodies; Lewy Body Disease; Microscopy, Immunoelectron; Multiple System Atrophy; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Oxidative Stress; Parkinson Disease; Synucleins; Tyrosine | 2000 |
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Disease Progression; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 2002 |
The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cattle; Nerve Tissue Proteins; Nitric Oxide; Oxidation-Reduction; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Peroxynitrous Acid; Serum Albumin, Bovine; Superoxide Dismutase; Synucleins; Tyrosine | 2002 |
3-OMD and homocysteine plasma levels in parkinsonian patients.
Topics: Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 2002 |
CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.
Topics: Aged; Brain; Brain Diseases; Dementia; Diabetic Coma; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Middle Aged; Parkinson Disease; Tyrosine; Tyrosine 3-Monooxygenase | 1978 |
Dopaminergic supersensitivity in parkinsonism.
Topics: Aged; Benzyl Compounds; Brain; Brain Chemistry; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Nerve Degeneration; Norepinephrine; Parkinson Disease; Psychoses, Substance-Induced; Serotonin; Tryptophan; Tyrosine | 1975 |
[The effect of amphetamine stereoisomers on the function of dopamine synapses in vitro].
Topics: Adenylyl Cyclases; Amphetamines; Animals; Corpus Striatum; Dopamine; In Vitro Techniques; Male; Parkinson Disease; Rats; Synapses; Synaptosomes; Tyrosine | 1975 |
Modification of the actions of some neuroactive drugs by growth hormone.
Topics: Animals; Apomorphine; Behavior, Animal; Dihydroxyphenylalanine; Dopamine; Drug Synergism; Growth Hormone; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Psychotropic Drugs; Tyrosine | 1976 |
The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies.
Topics: Aged; Amino Acids; Animals; Biogenic Monoamines; Corpus Striatum; Dialysis; Dopamine; Female; Humans; In Vitro Techniques; Kinetics; Levodopa; Male; Middle Aged; Neurons; Parkinson Disease; PC12 Cells; Rats; Tryptophan Hydroxylase; Tyrosine; Tyrosine 3-Monooxygenase | 1992 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disease; Kynurenic Acid; Kynurenine; Middle Aged; Parkinson Disease; Purines; Tryptophan; Tyrosine | 1992 |
Kynurenine pathway abnormalities in Parkinson's disease.
Topics: Aged; Autopsy; Brain; Female; Humans; Kynurenine; Male; Parkinson Disease; Tryptophan; Tyrosine | 1992 |
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Topics: Biogenic Monoamines; Biomarkers; Carbidopa; Humans; Levodopa; Middle Aged; Parkinson Disease; Tyrosine | 1991 |
Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
Topics: Aged; Dihydroxyphenylalanine; Dopamine; Humans; Middle Aged; Parkinson Disease; Tyrosine | 1991 |
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Levodopa; Macaca fascicularis; Male; Nitriles; Parkinson Disease; Pentanones; Tyrosine | 1991 |
[L-tyrosine: a long term treatment of Parkinson's disease].
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
Topics: Aged; Aged, 80 and over; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Phenytoin; Time Factors; Tyrosine | 1989 |
[The changes in noradrenaline content in CSF of patients under electroacupuncture].
Topics: Acupuncture Therapy; Adolescent; Adult; Anesthesia; Brain Neoplasms; Electric Stimulation Therapy; Humans; Norepinephrine; Parkinson Disease; Serotonin; Transcutaneous Electric Nerve Stimulation; Tyrosine | 1988 |
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Tyrosine | 1987 |
3-O-methyldopa and the response to levodopa in Parkinson's disease.
Topics: Administration, Oral; Blood-Brain Barrier; Humans; Infusions, Intravenous; Levodopa; Parkinson Disease; Tyrosine | 1987 |
Effects of tyrosine administration on plasma biopterin in patients with juvenile parkinsonism and their relatives.
Topics: Adult; Biopterins; Female; Humans; Middle Aged; Parkinson Disease; Pedigree; Tyrosine | 1987 |
Determination of tyrosine, tryptophan and their metabolic derivatives by liquid chromatography-electrochemical detection: application to post mortem samples from patients with Parkinson's and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Chromatography, High Pressure Liquid; Electrochemistry; Female; Humans; Male; Middle Aged; Parkinson Disease; Rats; Tryptophan; Tyrosine | 1985 |
Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Tryptophan; Tyrosine | 1985 |
Determination of m- and p-O-methylated products of L-3,4-dihydroxyphenylalanine using high-performance liquid chromatography and electrochemical detection.
Topics: Animals; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Isomerism; Levodopa; Liver; Methylation; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1985 |
Tyrosine hydroxylase deficiency. A unifying concept of Parkinsonism.
Topics: Age Factors; Dihydroxyphenylalanine; Dopamine; Dopamine Antagonists; Humans; Mixed Function Oxygenases; Parkinson Disease; Reserpine; Substantia Nigra; Tyrosine | 1971 |
Tyrosine hydroxylation in Parkinsonism.
Topics: Amino Acid Metabolism, Inborn Errors; Humans; Mixed Function Oxygenases; Parkinson Disease; Tyrosine | 1971 |
Tyrosine hydroxylase and parkinsonism.
Topics: Animals; Brain; Carbon Monoxide; Catecholamines; Dopamine; Haplorhini; Humans; Manganese; Mixed Function Oxygenases; Parkinson Disease; Parkinson Disease, Secondary; Serotonin; Substantia Nigra; Tyrosine | 1971 |
Melanocyte-stimulating hormone and parkinsonism.
Topics: Adolescent; Adult; Aged; Animals; Catechol Oxidase; Dermatitis, Seborrheic; Dopamine; Feedback; Female; Humans; Hypophysectomy; Hypothalamus; Male; Melanocyte-Stimulating Hormones; Mesencephalon; Middle Aged; Parkinson Disease; Pituitary Gland; Rats; Sebum; Substantia Nigra; Tyrosine | 1973 |
Melanocyte-stimulating hormone and parkinsonism.
Topics: Dihydroxyphenylalanine; Humans; Melanocyte-Stimulating Hormones; Parkinson Disease; Tyrosine | 1973 |
Levodopa and melanoma.
Topics: Catechol Oxidase; Dihydroxyphenylalanine; Humans; Male; Melanocytes; Melanoma; Parkinson Disease; Skin; Tyrosine | 1973 |
[Experimental findings and new aspects in extrapyramidal diseases].
Topics: 5-Hydroxytryptophan; Blood Pressure; Body Temperature Regulation; Chorea; Dihydroxyphenylalanine; Dopamine; Humans; Monoamine Oxidase Inhibitors; Movement Disorders; Norepinephrine; Parkinson Disease; Perphenazine; Phenylalanine; Reserpine; Serotonin; Tyrosine | 1966 |
[Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)].
Topics: Aged; Carboxy-Lyases; Catecholamines; Chorea; Dihydroxyphenylalanine; Female; Humans; Hydrazines; Male; Middle Aged; NAD; Oxidoreductases; Parkinson Disease; Phenylalanine; Tyrosine | 1967 |
Juvenile parkinsonism.
Topics: Adult; Age Factors; Aged; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine; Humans; Male; Metabolism, Inborn Errors; Mixed Function Oxygenases; Parkinson Disease; Parkinson Disease, Secondary; Pedigree; Spasm; Tranquilizing Agents; Tremor; Tyrosine; Tyrosine 3-Monooxygenase | 1971 |
Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
Topics: Administration, Oral; Aged; Carbon Radioisotopes; Decarboxylation; Dihydroxyphenylalanine; Dopamine; Female; Humans; Injections, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylalanine; Stimulation, Chemical; Sulfates; Tyrosine | 1974 |
Effect of L-DOPA on the synthesis and excretion of tyramine.
Topics: Animals; Brain Stem; Caudate Nucleus; Cerebellum; Dopamine; Humans; Hypothalamus; Levodopa; Octopamine; Pargyline; Parkinson Disease; Rats; Time Factors; Tritium; Tryptamines; Tyramine; Tyrosine | 1974 |
L-dopa in Parkinsonism. A possible mechanism of action.
Topics: Amines; Animals; Basal Ganglia; Brain; Carbon Isotopes; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Frontal Lobe; Hydroxydopamines; Methyldopa; Norepinephrine; Parkinson Disease; Rats; Serotonin; Tritium; Tyrosine; Urea | 1972 |
[Symposium: metabolism in neurogical disorders. 1. Parkinsonism. 1-(1). Metabolic disturbance in Parkinsonism].
Topics: Amino Acids; Catecholamines; Dopamine; Humans; Parkinson Disease; Tyrosine | 1972 |
Monitoring phenylalanine-tyrosine metabolism by high-resolution liquid chromatography of urine.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Autistic Disorder; Carbidopa; Catechols; Child; Chromatography, Gas; Chromatography, Ion Exchange; Dihydroxyphenylalanine; Hippurates; Homovanillic Acid; Humans; Hyperkinesis; Intellectual Disability; Lactates; Mandelic Acids; Mass Spectrometry; Methods; Nervous System Diseases; Parkinson Disease; Phenylacetates; Phenylalanine; Spectrophotometry, Ultraviolet; Tyrosine | 1973 |
L-m-tyrosine and Parkinsonism.
Topics: Animals; Humans; Parkinson Disease; Tyrosine | 1973 |
[Implications of the formulation of m-tyrosine from DOPA for Parkinsonism].
Topics: Animals; Catecholamines; Chemoreceptor Cells; Dihydroxyphenylalanine; Humans; Parkinson Disease; Tyrosine | 1974 |
Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.
Topics: Aged; Amygdala; Autopsy; Biogenic Amines; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Globus Pallidus; Gyrus Cinguli; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Norepinephrine; Parkinson Disease; Psychoses, Substance-Induced; Red Nucleus; Serotonin; Substantia Nigra; Tryptophan; Tyrosine | 1974 |
Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man.
Topics: Brain Chemistry; Chromatography; Dihydroxyphenylalanine; Dopamine; Humans; Intestines; Parkinson Disease; Tyramine; Tyrosine | 1971 |
Effects of globus pallidus lesions and Parkinson's disease on brain glutamic acid decarboxylase.
Topics: Acetylcholinesterase; Aminobutyrates; Animals; Carbon Isotopes; Carboxy-Lyases; Cats; Caudate Nucleus; Choline; Globus Pallidus; Glutamates; Humans; Mixed Function Oxygenases; Parkinson Disease; Stereotaxic Techniques; Substantia Nigra; Tyrosine | 1971 |
[The strio-pallidal system and its accessory mechanisms in relation to extra-pyramidal physiopathology].
Topics: Animals; Dopamine; Extrapyramidal Tracts; Haplorhini; Humans; Parkinson Disease; Psychomotor Disorders; Thalamus; Tyrosine | 1970 |
[Motor and psychomotor activity of striatal monoamines].
Topics: Animals; Basal Ganglia; Catecholamines; Depression, Chemical; Dihydroxyphenylalanine; Dopamine; Globus Pallidus; Haplorhini; Monoamine Oxidase; Motor Neurons; Movement Disorders; Norepinephrine; Parkinson Disease; Serotonin; Tyrosine | 1970 |
Analysis in human plasma of 3-methoxytyrosine: a metabolite of DOPA.
Topics: Chromatography, Ion Exchange; Dihydroxyphenylalanine; Ethers; Fasting; Humans; Mass Spectrometry; Parkinson Disease; Phenylalanine; Tyrosine | 1971 |
Phenylalanine absorption and metabolism in Parkinsonian patients.
Topics: Administration, Oral; Aged; Female; Half-Life; Humans; Injections, Intravenous; Intestinal Absorption; Male; Middle Aged; Parkinson Disease; Phenylalanine; Tyrosine | 1971 |
[Experimental and clinical data on the mechanism of action of amantadine and on its effectiveness in Parkinson's disease].
Topics: Acetylcholine; Aged; Amantadine; Amphetamine; Animals; Brain; Female; Guinea Pigs; Humans; Male; Middle Aged; Parkinson Disease; Tyrosine | 1971 |
Tyrosine metabolism: urinary excretion studies in Parkinsonism.
Topics: Body Weight; Chromatography, Gas; Chromatography, Ion Exchange; Chromatography, Thin Layer; Colorimetry; Dihydroxyphenylalanine; Female; Homogentisic Acid; Humans; Male; Middle Aged; Parkinson Disease; Phenylacetates; Tyrosine; Vanilmandelic Acid | 1971 |
The effect of L-dopa on monoamine metabolites in Parkinson's disease.
Topics: 5-Hydroxytryptophan; Aged; Dihydroxyphenylalanine; Dopamine; Humans; Hydroxyindoleacetic Acid; Middle Aged; Mixed Function Oxygenases; Parkinson Disease; Phenylacetates; Serotonin; Stereoisomerism; Tyrosine | 1970 |
Parahydroxyphenylpyruvic acid excretion in parkinsonism.
Topics: Adult; Age Factors; Aged; Body Weight; Chronic Disease; Female; Humans; Male; Middle Aged; Parkinson Disease; Phenylpyruvic Acids; Tyrosine | 1970 |
Dopamine: stimulation-induced release from central neurons.
Topics: Animals; Basal Ganglia; Brain; Carbon Isotopes; Depression, Chemical; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Electric Stimulation; In Vitro Techniques; Male; Neurons; Parkinson Disease; Phenethylamines; Rats; Tritium; Tyrosine | 1971 |
[The protein nature of specific cellular inclusions (Lewy's bodies) in Parkinson's disease].
Topics: Acetylcholinesterase; Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Cholinesterases; Cystine; Cytoplasmic Granules; Histidine; Histocytochemistry; Humans; Lipase; Lysine; Microscopy, Electron; Neurons; Parkinson Disease; Proteins; Substantia Nigra; Sulfites; Tryptophan; Tyrosine | 1967 |
L-dopa in Parkinson's syndrome.
Topics: Brain; Catecholamines; Dihydroxyphenylalanine; Humans; Melanins; Nervous System Diseases; Parkinson Disease; Substantia Nigra; Tyrosine | 1969 |
Oral phenylalanine and tyrosine tolerance tests in Parkinsonian patients.
Topics: Adult; Aged; Female; Humans; Intestinal Absorption; Male; Middle Aged; Parkinson Disease; Phenylalanine; Statistics as Topic; Tyrosine; Xylose | 1969 |